Pharmaceuticals company Piramal Pharma announced Q2FY25 results Revenue from Operations grew by 17% YoY, primarily driven by robust growth in CDMO business. EBITDA grew by 28% YoY with EBITDA margin of 18%, a YoY improvement of about 150bps, driven by operating leverage, cost optimization initiatives and superior revenue mix. Released our FY24 Sustainability Report. The report follows GRI standards and is aligned with SASSB and UNGC frameworks. It also highlights our commitment to reduce our GHG emissions inline with SBTi’s 1.5 decarbonization pathway. Nandini Piramal, Chairperson, Piramal Pharma said: “We continue our momentum of delivering healthy revenue growth accompanied by YoY EBITDA margin expansion. This has been primarily driven by consistent growth in our CDMO business which has witnessed a good pick-up in innovation related work and on-patent commercial revenues. To sustain this growth momentum and to capitalize on rising demand for sterile fill-finish capabilities, we have announced a US USD 80 million expansion plan at our Lexington facility which is expected to get complete by end FY27. In our CHG business, we are witnessing steady volume growth in Inhalation Anesthesia products in the US and Emerging Markets. In our ICH business, we continue to see a robust growth in our power brands and e-commerce sales. During the quarter, we released our Sustainability Report for FY24 under the theme, ‘Building Resilience for a Sustainable Tomorrow’, highlighting our progress on the sustainability initiatives. Over the long term, we remain committed to achieving our financial goals of US USD 2 billion revenue with 25% EBITDA margin and 1x net debt / EBITDA by FY30.” Result PDF